In short
Ficlatuzumab is an investigational drug being studied in clinical trials for various types of cancer. This monoclonal antibody targets hepatocyte growth factor (HGF) and its receptor c-Met, which are involved in cancer growth and spread. Researchers are evaluating ficlatuzumab alone and in combination with other treatments to determine its safety and effectiveness for cancers like head and neck squamous cell carcinoma, non-small cell lung cancer, acute myeloid leukemia, and pancreatic cancer.
At a glance
- Drug Name
- Ficlatuzumab (also known as AV-299, SCH 900105)
- Drug Type
- Humanized anti-hepatocyte growth factor (HGF) monoclonal antibody
- Mechanism of Action
- Targets HGF and its receptor c-Met, inhibiting cancer growth and spread
- Administration
- Intravenous infusion, typically every 2 weeks
- Cancer Types Studied
- Head and neck squamous cell carcinoma, Non-small cell lung cancer, Acute myeloid leukemia, Pancreatic cancer
- Combination Therapies
- Studied with cetuximab, erlotinib, cisplatin, gemcitabine, nab-paclitaxel, and radiotherapy
- Key Outcomes Measured
- Safety, tolerability, maximum tolerated dose, progression-free survival, overall survival, response rate
- Biomarker Studies
- Evaluating HGF and c-Met expression, mutations in PIK3CA, PTEN, and HRAS, immune cell phenotypes
What is Ficlatuzumab?
Ficlatuzumab is an investigational drug being studied for the treatment of various types of cancer. It is a type of medication known as a monoclonal antibody, which is a laboratory-made protein designed to target specific cells in the body. Ficlatuzumab is also known by other names, including AV-299 and SCH 900105.
How Does Ficlatuzumab Work?
Ficlatuzumab works by targeting a protein called hepatocyte growth factor (HGF). HGF is involved in cell growth and survival, and it can sometimes contribute to the growth of cancer cells. By blocking HGF, ficlatuzumab aims to slow down or stop the growth of cancer.
More specifically, ficlatuzumab is a humanized anti-HGF monoclonal antibody. This means it's designed to be similar to human antibodies, which helps reduce the chances of the body rejecting it. By inhibiting HGF, ficlatuzumab may help prevent cancer cells from growing and spreading.
Cancers Treated with Ficlatuzumab
Ficlatuzumab is being studied for the treatment of several types of cancer, including:
- Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that starts in the cells lining the mouth, nose, and throat.
- Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer.
- Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow.
- Pancreatic Cancer: A cancer that develops in the pancreas, an organ behind the stomach.
- Ovarian Cancer: Specifically, a rare type called Mullerian Mixed Tumor of Ovary.
Ficlatuzumab in Clinical Trials
Ficlatuzumab is currently being tested in various clinical trials to determine its safety and effectiveness. These trials are investigating ficlatuzumab both alone and in combination with other cancer treatments. Some notable studies include:
- A study combining ficlatuzumab with erlotinib (another cancer drug) for treating lung cancer.
- A trial testing ficlatuzumab with gemcitabine and nab-paclitaxel for pancreatic cancer.
- Research on ficlatuzumab with cetuximab for head and neck cancer.
- A study using ficlatuzumab with cisplatin and radiation therapy for head and neck cancer.
Administration and Dosage
Ficlatuzumab is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific trial and the type of cancer being treated. For example:
- In some studies, it's given every two weeks.
- The dose may range from 10 mg/kg to 20 mg/kg, depending on the trial.
- The infusion usually takes between 30 to 60 minutes.
Potential Side Effects
As ficlatuzumab is still in clinical trials, all of its potential side effects are not yet fully known. Researchers are closely monitoring patients for any adverse reactions. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts. It's important to report any unusual symptoms to your healthcare provider if you're participating in a clinical trial.
Future Prospects
The ongoing clinical trials will help determine ficlatuzumab's effectiveness and safety profile. If successful, it could potentially offer a new treatment option for patients with various types of cancer, especially those who haven't responded well to other treatments. However, it's important to remember that as an investigational drug, ficlatuzumab is not yet approved for general use outside of clinical trials.